- |||||||||| levofloxacin / Generic mfg.
Journal: Mechanism of Anti-Inflammatory Drugs in the Early Treatment of Oral Gingival Mucosa and Soft Tissue Trauma. (Pubmed Central) - Oct 18, 2022
Then, the white-eared rabbits were treated with gingival wound treatment experiments, and the physiological characteristics, intratissue pressure, tissue partial pressure of oxygen, IL-6 content, and PGE2 content were determined at each postinjury period, and the mechanism of action of anti-inflammatory drugs was determined. Research results have shown that anti-inflammatory drugs can significantly inhibit the content of IL-6 and PGE2 in gingival soft tissue after injury, reduce the local inflammatory response, and accelerate tissue healing.
- |||||||||| levofloxacin / Generic mfg.
Journal: Enhanced electron transfer for activation of peroxymonosulfate via MoS modified iron-based perovskite. (Pubmed Central) - Oct 18, 2022
In this paper, SrFeO@MoS heterogeneous catalyst was prepared to activate peroxymonosulfate (PMS) for the degradation of levofloxacin (LVO)...Combining with the XPS characterization, the activation mechanism of SrFeO@MoS-0.3/PMS was proposed, and the oxygen vacancies and transition metals on the sample surface were active sites of PMS activation. Furthermore, the possible degradation pathways of LVO were well-established based on the detected intermediates.
- |||||||||| levofloxacin / Generic mfg.
Levofloxacin Dosing Recommendations for Home Hemodialysis (HHD) (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1096;
Conclusion One levofloxacin 500 mg tablet every 24h for E. coli and S. pneumoniae, and 750mg every 24h for P. aeruginosa would reach the PD target by day 2. However, clinical caution is warranted since this levofloxacin dosing recommendation is higher than those used for intermittent hemodialysis.
- |||||||||| levofloxacin / Generic mfg.
Journal: Fused deposition modelling 3D printing proof-of-concept study for personalised inner ear therapy. (Pubmed Central) - Oct 13, 2022
However, clinical caution is warranted since this levofloxacin dosing recommendation is higher than those used for intermittent hemodialysis. This proof-of-concept research was successful in utilising FDM as a fabrication method for a DDS capable of providing prolonged release directly to the inner ear and highlights the viability of 3DP in the fabrication of an inner ear DDS.
- |||||||||| Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard, NN1213 / Novo Nordisk
Trial completion date: STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (clinicaltrials.gov) - Oct 13, 2022
P3, N=588, Active, not recruiting,
This proof-of-concept research was successful in utilising FDM as a fabrication method for a DDS capable of providing prolonged release directly to the inner ear and highlights the viability of 3DP in the fabrication of an inner ear DDS. Trial completion date: Aug 2022 --> Apr 2023
- |||||||||| levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
Retrospective data, Review, Journal: The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis. (Pubmed Central) - Oct 12, 2022
Levofloxacin, Moxifloxacin, and Gatifloxacin have different superiority, comparing to CT regimen in spectrum culture negative, treatment success rate, and adverse events. Hence, combined utilization of these quinolone is important on the clinical treatment for tuberculosis.
- |||||||||| Journal: Co-infections of Aeromonas veronii and Nocardia seriolae in largemouth bass (Micropterus salmoides). (Pubmed Central) - Oct 11, 2022
In addition, the coinfection of A. veronii and N. seriolae induce quick and higher mortality in comparison with those challenged by single bacteria. These results revealed that both A. veronii and N. seriolae participated in the disease outbreaks of the M. salmoides, and concurrent of those two bacteria synergistically exacerbate the disease severity.
- |||||||||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Journal: A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen. (Pubmed Central) - Oct 11, 2022
CASE REPORT A 77-year-old man with chronic renal failure had an esophageal-skin fistula after he had surgeries for removal of esophageal and gastric cancers and reconstruction using jejunum, and he showed a cavity, tree-in-bud formation, and pleural effusions in his left upper lung fields on his chest X-ray after treatment of cellulitis and bacteremia/candidemia by meropenem, teicoplanin, and micafungin...Although he could not take antimycobacterial agents orally, treatment was started with intravenous agents combining levofloxacin (LVFX) every other day, isoniazid (INH), and linezolid (LZD)...The M. tuberculosis disappeared, and the abnormal chest X-ray shadows were improved 2 months after the start of treatment. CONCLUSIONS Administration of intravenous TZD, in addition to intravenous LVFX and intramuscular SM in combination, might be a candidate regimen for M. tuberculosis patients who cannot take oral medications.
- |||||||||| levofloxacin / Generic mfg.
Retrospective data, Review, Journal: Clinical Efficacy and Safety Analysis of Levofloxacin for the Prevention of Infection after Traumatic Osteoarthrosis and Internal Fixation: Systematic Review and Meta-Analysis. (Pubmed Central) - Oct 11, 2022
There was a statistical difference in the comparison of the incidence of fever between the experimental group and the control group (OR = 2.29, 95% CI (1.75,2.98),P < 0.00001, I = 0%, Z = 6.11); elevated white blood cell count (OR = 1.82, 95% CI (1.31,2.52),P=0.0003, I = 0%, Z = 3.60); incidence of wound infection (OR = 2.11, 95% CI (1.54,2.90),P < 0.00001, I = 0%, Z = 4.64); adverse drug reaction (OR = 1.82, 95% CI (1.21,2.74),P=0.004, I = 0%, Z = 2.86). In the clinical use of levofloxacin, adverse drug reactions including fever, elevated white blood cell count, and wound infection should be concerned.
- |||||||||| levofloxacin / Generic mfg., colistin sulphate / Generic mfg.
WITHDRAWN Genomic characterization of multidrug resistant travel-associated E. coli in U.S. international travelers (Convention Center - Hall 4A (4th Floor); In-Person-Only) - Oct 9, 2022 - Abstract #ASTMH2022ASTMH_1363;
In addition to ESBL carriage, 150 isolates were phenotypically resistant to levofloxacin. In summary, we identified strain-level genomic differences between travel-acquired and U.S.-associated E. coli, with an enrichment of phylogroup A isolates in association with travel and majority acquisition of the CTX-M-15 allele alongside widespread resistance to other antimicrobials.
- |||||||||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. (Pubmed Central) - Oct 9, 2022
The presence of diarrhoea causing pathogens and microbes in food and corresponding faecal samples indicate the high risk of faeco-oral transmission among the consumers and high antibiotic resistance rates by multiple bacteria indicate the urgent need to ensure the food quality. Ceftaroline showed good activity among tested antimicrobial agents against Gram-positive species, while ceftazidime-avibactam had good activity against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Morganella morganii, Serratia marcescens and Pseudomonas aeruginosa excluding carbapenem-resistant isolates.
- |||||||||| Impact of highly effective modulator therapy on the cystic fibrosis microbiome (Exhibition Hall) - Oct 8, 2022 - Abstract #NACFC2022NACFC_1208;
aeruginosa–colonized adults with CF treated with HEMT had a decrease in colonization rate of P. aeruginosaand improvement in susceptibility to common antibiotic therapy. Larger studies are needed toconfirm this potential positive impact on the microbiome of adults with CFreceiving HEMT.678 Role of adenylate cyclase 6 autophagy complex in the rescue andfunction of F508del cystic fibrosis transmembrane conductanceregulator protein
- |||||||||| Journal: Antimicrobial resistance and genomic investigation of non-typhoidal Salmonella isolated from outpatients in Shaoxing city, China. (Pubmed Central) - Oct 7, 2022
Furthermore, the phylogenomic analysis showed that all isolates of the same serovar are very close to each other and clustered together in the same clade. Together, we showed a high incidence of MDR among the studied isolates which is alarming for public health services and is a major threat to the currently available treatments to deal with human salmonellosis; hence, efforts should be gathered to further introduce WGS in routinely monitoring of AMR Salmonella in the medical field in order to enhance the effectiveness of surveillance systems and to limit the spread of MDR clones.
- |||||||||| levofloxacin / Generic mfg.
Preclinical, Journal: Synthesis and antibacterial activity studies in vitro of indirubin-3'-monoximes. (Pubmed Central) - Oct 7, 2022
In addition, relevant experiments including electron microscopy observations, PI staining and the leakage of extracellular potassium ions and nucleic acid (260 nm) have been performed after treating S. aureus with indirubin-3'-monoxime 5aa, and the results revealed that indirubin-3'-monoximes could increase the cell membrane permeability of S. aureus. Although indirubin-3'-monoxime 5aa showed some cytotoxicity toward SH-SY5Y cells relative to compounds 5r and 5s, the skin irritation test of male mice after shaving showed that compound 5aa at a concentration of 12.8 μg mL had no toxicity to mouse skin, and it could be used as a leading compound for skin antibacterial drugs.
- |||||||||| levofloxacin / Generic mfg.
Levofloxacin-resistant Helicobacter pylori in Australia: A growing issue for refractory infection () - Oct 4, 2022 - Abstract #AGW2022AGW_557;
The high rate of levofloxacin resistance (>20%) raises substantial concern about recommending the use of levofloxacin in empirical second-line regimens. Increased awareness of current H. pylori resistance rates in Australia is needed to guide local eradication practices, and current antimicrobial prescribing guidelines for both primary and secondary therapy need to be revisited.
- |||||||||| levofloxacin / Generic mfg., clindamycin phosphate / Generic mfg., tetracycline / Generic mfg.
Journal: Adsorption characteristics of N-rGO for multiple representative trace antibiotics in water. (Pubmed Central) - Sep 30, 2022
The results indicated that N-rGO rapidly and effectively adsorbed trace antibiotics in water, thus providing a basis for constructing an adsorption-catalytic oxidation system. Overall, the proposed method is excellent for treating trace antibiotics in a water environment.
- |||||||||| Review, Journal: The perspective of antibiotic therapeutic challenges of brucellosis in the Middle East and North African (MENA) countries: Current situation and therapeutic management. (Pubmed Central) - Sep 30, 2022
However, several studies proved that brucellae are still in-vitro susceptible to the majority of antibiotic compounds and combinations in current recommended WHO treatment regimens, e.g. levofloxacin, tetracyclines, doxycycline, streptomycin, ciprofloxacin, chloramphenicol, gentamicin, tigecycline, and trimethoprim/sulfamethoxazole. The current review presents an overview on resistance development of brucellae and highlights the current knowledge on effective antibiotics regimens for treating human brucellosis.
- |||||||||| Journal: Simultaneous determination of 40 plant growth regulators, fungicides, insecticides, and antibiotics in bean sprouts by QuEChERS-high performance liquid chromatography-tandem mass spectrometry (Pubmed Central) - Sep 30, 2022
The contents ranged from 37.5-352.4, 32.4-273.1, 28.8-38.7, 316.1-20.2, 19.9 and 13.6 μg/kg, respectively. Given its advantages of simplicity, rapidness, and high sensitivity, the developed method can be used for the rapid and accurate determination of trace levels of the 40 drug residues in large quantities of bean sprouts.
- |||||||||| Invanz (ertapenem) / Merck (MSD)
Journal: Analysis of the Distribution and Antibiotic Resistance of Pathogens Causing Infections in Hospitals from 2017 to 2019. (Pubmed Central) - Sep 29, 2022
The distribution of pathogenic bacteria in different hospital departments and sample sources was markedly different. Therefore, targeted prevention and control of key pathogenic bacteria in different hospital departments is necessary, and understanding both drug resistance and multiple drug resistance of the main pathogenic bacteria may provide guidance for the rational use of antibiotics in the clinic.
- |||||||||| FDA event, Journal: Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs. (Pubmed Central) - Sep 29, 2022
The Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of gyration (Rg), and binding energy values obtained after 100 ns of MDS revealed good stability of these compounds in the binding sites of the proteins while important pharmacophore features were also identified. The study showed that COVID-19 likely originated from bat, owing to the over 90% genomic similarity observed, and that lopinavir, levofloxacin, and hydroxychloroquine might serve as potential anti-COVID-19 lead molecules for additional optimization and drug development for the treatment of COVID-19.Communicated by Ramaswamy H. Sarma.
- |||||||||| azithromycin / Generic mfg.
Journal: Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure. (Pubmed Central) - Sep 29, 2022
Azithromycin vs. levofloxacin treatment was associated with lower relative and absolute risks of sudden cardiac death, weighted hazard ratio of 0.79 (0.64 to 0.96) and weighted risk difference per 100,000 treatment episodes of -18.9 (-35.5 to -3.8). Thus, when selecting among azithromycin, levofloxacin, and amoxicillin-based antibiotics, clinicians should weigh the relative antimicrobial benefits of these drugs against their potential cardiac risks.
|
